ENDRA Life Sciences Inc.
NDRA
$6.46
$1.1922.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.83% | 48.55% | -69.56% | 31.35% | -39.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.00% | 47.94% | -62.25% | -9.17% | -41.68% |
| Operating Income | -14.00% | -47.94% | 62.25% | 9.17% | 41.68% |
| Income Before Tax | 113.04% | -26.55% | 23.62% | 32.20% | 45.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 113.04% | -26.55% | 23.62% | 32.20% | 45.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 113.04% | -26.55% | 23.62% | 32.20% | 45.01% |
| EBIT | -14.00% | -47.94% | 62.25% | 9.17% | 41.68% |
| EBITDA | -14.20% | -48.70% | 62.39% | 9.19% | 41.87% |
| EPS Basic | 107.07% | 41.18% | 62.88% | 78.02% | 98.80% |
| Normalized Basic EPS | 106.64% | 40.69% | 78.65% | 78.02% | 98.80% |
| EPS Diluted | 103.51% | 41.18% | 62.88% | 78.02% | 98.80% |
| Normalized Diluted EPS | 103.55% | 40.69% | 78.65% | 78.02% | 98.80% |
| Average Basic Shares Outstanding | 84.63% | 115.14% | 105.80% | 208.43% | 4,496.79% |
| Average Diluted Shares Outstanding | 245.18% | 115.14% | 105.80% | 208.43% | 4,496.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |